Phase 3 Psoriasis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are between 18 and 70 years old (any gender, race, or ethnic background)
- You have been diagnosed with stable plaque psoriasis and have at least two affected skin areas that can be assessed during the trial
- If you are a woman who could become pregnant, you must be using a barrier method (such as a condom) and/or oral contraceptives throughout the 8-week study
- Your psoriasis has been rated as at least "mild" based on a standard medical scoring system (confirm with trial site)
- The affected skin area covers between 1% and 20% of your body
- You are willing and able to sign a consent form agreeing to take part
- You agree to avoid extra sun exposure during the study
Who may not be able to join:
- You are currently pregnant, trying to become pregnant, or breastfeeding
- You have a history of severe allergic reactions or unusual sensitivity to sunlight
- You have a history of serious heart, brain, liver, kidney, or blood disorders, or a psychiatric condition
- You have or have had a condition that causes sensitivity to light, such as porphyria, chronic actinic dermatitis, or Xeroderma pigmentosum
- You have used certain psoriasis treatments on the affected skin areas within the past 4 weeks, including creams or ointments, specific light therapies (PUVA, UVB, or Grenz ray), or certain other systemic (whole-body) medications or experimental treatments
- You have used retinoid medications or certain biologic therapies for psoriasis within the past 3 months (confirm with trial site for the specific medications involved)
- You are planning to start or change any medications during the study that could affect psoriasis, such as beta blockers, anti-malaria drugs, or lithium
- You have had an allergic reaction to substances chemically similar to Coumarins (confirm with trial site)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Liping Yang, MD, Psoriasis Research Institute of Guangzhou
Phone: +1-(608)-772-1251
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Investigator's Global Assessment (IGA) (5-point scale)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.